# Merck & Co. Inc. (MRK)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/MRK/primer

## Business Model

---
ticker: MRK
step: 01
generated: 2026-05-11
source: quick-research
---

### Merck & Co., Inc. (MRK) — Business Overview

#### Business Description
Merck is one of the world's largest pharmaceutical companies, anchored by **Keytruda** (pembrolizumab) — the best-selling oncology drug in history ($29.5B in 2024 sales, projected ~$32.7B peak in 2026). The company sells branded pharmaceuticals, vaccines, and animal health products globally. Merck's strategic identity for 2026–28 is dominated by one question: **how does it absorb the Keytruda patent cliff in 2028?** Management is responding through (1) Keytruda subcutaneous (Keytruda QLEX) for IV-to-SC conversion, (2) splitting oncology into a standalone business unit, (3) aggressive M&A ($10B Verona + $6.7B Terns + smaller deals), and (4) accelerating WINREVAIR (PAH) and other pipeline launches.

#### Revenue Model
Single reportable segment ("Pharmaceutical"), but with several franchise groupings:
- **Oncology** — Keytruda (~45% of total revenue), Welireg, Lynparza (royalty from AZ partnership), Lenvima (royalty), and pipeline.
- **Vaccines** — Gardasil/Gardasil 9 (HPV), Pneumovax, ProQuad (MMRV), Vaxneuvance, Capvaxive (pneumococcal), Rotateq.
- **Cardiovascular / Pulmonary** — WINREVAIR (PAH), Ohtuvayre (COPD, post-Verona acquisition), Adempas (royalty), Verquvo, Bridion.
- **Diabetes / Hospital Acute Care** — Januvia/Janumet (off-patent), Bridion, Zerbaxa, Inhalation anesthesia.
- **Antiviral / Other** — Lagevrio (Covid), Isentress, Pifeltro.
- **Animal Health** — Companion animal + livestock pharmaceuticals (Bravecto, vaccines).

Revenue mix is heavily skewed to Keytruda — the single largest concentration risk in mega-cap pharma.

#### Products & Services
- **Keytruda** — PD-1 inhibitor approved in 40+ indications across 20+ tumor types; the cornerstone oncology asset.
- **Keytruda QLEX** — Subcutaneous pembrolizumab formulation (FDA approved); aims for 30–40% conversion by 2028.
- **Welireg** (HIF-2α) — Newer oncology asset (renal cell carcinoma).
- **Gardasil 9** — HPV vaccine; China shipment freeze in 2025 was a multi-quarter drag.
- **WINREVAIR** — PAH (activin inhibitor); 12-yr US biologics exclusivity (potentially to 2037); $419M in 2024, ramping toward $5–10B peak.
- **Ohtuvayre (ensifentrine)** — First-in-class COPD maintenance; potential blockbuster from Verona acquisition (closed late 2025).
- **Pipeline (selected):** TIGIT/PD-1 (vibostolimab), MK-7264 (TL1A IBD), oral PCSK9 (Eylea-class), Terns CML asset, plus oncology pipeline rebuilding.

#### Customer Base & Go-to-Market
- **Oncology**: Hospitals, academic medical centers, oncology specialty pharmacies. ~30,000+ sales reps globally.
- **Vaccines**: Governments (Gardasil school-age programs), pediatricians, pharmacies, employers; large public-tender dependency.
- **Animal Health**: Veterinary clinics, livestock producers; distributed through veterinary distributors.
- **Geography**: ~50% US, ~50% international. China is critical for Gardasil (recovering); EU/Japan/EM for Keytruda and other oncology.

#### Competitive Position
- **Oncology** — Keytruda is the dominant PD-1 globally (~70%+ market share among PD-1s); Opdivo (BMS) is the primary competitor. Pipeline gap relative to competitors (Roche tiragolumab, BMS Opdivo subQ + relatlimab combo, AstraZeneca Imfinzi, Daiichi/AZ DXd ADCs) is the single biggest structural issue.
- **Vaccines** — Gardasil 9 is the global standard for HPV; ProQuad/MMR-V are best-in-class for childhood vaccines; new Capvaxive pneumococcal targets adults.
- **PAH** — WINREVAIR is best-in-class entry; competing with Opsumit (J&J) and Uptravi (J&J) but with novel MOA.
- **Animal Health** — Top 3 globally with Zoetis and Elanco.

**Structural risks**: (1) Keytruda 2028 patent cliff (US composition-of-matter expires); (2) ~$25B+ revenue at risk over 2028–32; (3) pipeline depth vs. peers; (4) IRA Medicare price negotiations expanded to more drugs starting 2026.

#### Key Facts
- Founded: 1891
- Headquarters: Rahway, New Jersey
- Employees: ~71,000
- Exchange: NYSE
- Sector / Industry: Health Care / Pharmaceuticals
- Market Cap: ~$200B
- 2024 Revenue: $64.2B
- 2025 Revenue Guide: $64.1–65.6B
- Major Acquisitions Recent: Verona Pharma ($10B, Ohtuvayre COPD); Terns Pharma ($6.7B, CML); Prometheus ($10.8B, MK-7240 TL1A); Acceleron ($11.5B, WINREVAIR predecessor)

## Financial Snapshot

---
ticker: MRK
step: 04
generated: 2026-05-11
source: quick-research
---

### Merck & Co., Inc. (MRK) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2023 | FY2024 | FY2025 | YoY (FY25) |
|--------|--------|--------|--------|------------|
| Revenue | $60.1B | $64.2B | $65.0B | +1.3% |
| Keytruda Revenue | $25.0B | $29.5B | $31.7B | +7% |
| Adjusted Operating Margin | ~40% | ~42% | ~43% | +100 bps |
| GAAP EPS | $0.14* | $6.74 | $7.28 | +8% |
| Adjusted EPS | $6.74 | $7.65 | $8.98 | +17% |

*FY2023 GAAP EPS depressed by ~$10B Prometheus + ~$5.5B Daiichi-Sankyo IPR&D charges.

#### Top Products (FY2025)

| Product | FY25 Sales | YoY | Notes |
|---------|------------|-----|-------|
| Keytruda + Keytruda QLEX | $31.7B | +7% | QLEX SC contributed $35M in Q4 (early launch) |
| Gardasil 9 | ~$8.2B | -5% | China shipment freeze pressure |
| WINREVAIR (PAH) | $1.4B | NM | Ramping toward multi-billion peak |
| Animal Health | $6.4B | +8% | Strong companion + livestock |
| Lagevrio (Covid) | declining | NM | Endemic phase |

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$18B |
| Capital Expenditures | ~$5B |
| Free Cash Flow | $12.4B (FY25) |
| Free Cash Flow Target (FY27) | ~$24B |
| Dividend (Quarterly) | $0.81 |
| Annual Dividend Yield | ~2.9% |
| Dividend Payout Ratio | ~44% (earnings); ~68% (cash) |
| Cash & Marketable Securities | ~$13B |
| Total Debt | ~$36B |
| Major Recent Acquisitions | Verona ($10B), Terns ($6.7B), Cidara (~$9B charge in Q1 2026) |

#### Key Ratios (approximate)
- P/E: ~9x (FY25 adjusted EPS) | EV/EBITDA: ~8x | FCF Yield: ~6% (depressed by IPR&D charges)
- Revenue Growth (FY25): +1.3% | Adjusted EPS Growth: +17%
- Dividend Yield: ~2.9%; payout ratio ~44% of earnings
- Operating Margin: ~43% (adjusted)

#### Growth Profile
2025 was the last "clean" year before the 2028 Keytruda patent cliff dominates the narrative. Revenue +1.3% nominally (Gardasil China + Lagevrio Covid both significant drags); adjusted EPS +17% on operating leverage and lower charges. Key forward dynamics:

**2026–27**: Keytruda continues growing toward ~$32B+ peak (2026); Keytruda QLEX (subcutaneous) launching to convert IV patients ahead of biosimilars. WINREVAIR ramping; Ohtuvayre (from Verona) launching; pipeline asset readouts. ~$24B FCF target for 2027.

**2028+**: Keytruda US loss of exclusivity. Bear case: ~50%+ of Keytruda IV revenue lost over 2028–32 to biosimilars; revenue declines 15–25% from peak. Bull case: 30–40% conversion to Keytruda QLEX (12-yr biologic exclusivity) preserves $9–12B; pipeline (WINREVAIR, Ohtuvayre, MK-7240 TL1A, Terns CML, oral PCSK9) replaces lost revenue.

#### Forward Estimates
2026 Guide (initial):
- Revenue: $65.5–67B (vs. $67.6B consensus — modest miss)
- Adjusted EPS: $5.00–5.15 (vs. $5.36 consensus — includes ~$3.65 one-time Cidara acquisition charge)
- Underlying EPS (ex-Cidara charge): $8.65–8.80, roughly flat YoY

Sell-side estimates have material divergence on 2028+. Bull case: $24B+ FCF / share at 2027 trough, recovery to growth by 2030 via pipeline. Bear case: 2028–30 trough in EPS at ~$5–6/share with multiple compression to ~8x P/E.

## Recent Catalysts

---
ticker: MRK
step: 12
generated: 2026-05-11
source: quick-research
---

### Merck & Co., Inc. (MRK) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Keytruda QLEX (subcutaneous) IV-to-SC conversion** — Launched Q4 2025; if Merck converts 30–40% of Keytruda IV patients to QLEX (12-year biologics exclusivity through ~2037) by 2027, it preserves $9–12B of Keytruda revenue post-2028 biosimilar wave. The earliest IV biosimilars cannot match a fully-converted SC patient base.
2. **WINREVAIR (PAH) blockbuster trajectory** — $1.4B in FY25 (first full year); broker peak estimates $5–10B; 12-yr exclusivity to ~2037. Best-in-class activin inhibitor with novel MOA vs. PAH standard of care (Opsumit, Uptravi). Material WINREVAIR upside relative to consensus is the single largest pipeline driver to 2028+.
3. **Ohtuvayre (COPD) post-Verona acquisition** — $10B Verona deal acquired the first-in-class COPD maintenance therapy. Multi-billion peak potential in a large, underserved respiratory market.
4. **Aggressive M&A war chest deploying** — Verona ($10B) + Terns ($6.7B CML) + Cidara (~$9B charge in Q1 2026) + Prometheus ($10.8B MK-7240 TL1A IBD) + ongoing pipeline rebuilds. >$50B+ deployed since 2023 specifically targeting post-Keytruda revenue gap.
5. **Animal Health steady mid-single-digit growth** — $6.4B in FY25 (+8%); structurally less cyclical and less patent-dependent than human pharma. Possible spin-off optionality (Pfizer Zoetis precedent).
6. **Adjusted operating margin at 43% with operating leverage** — Best-in-class pharma operating margin. As pipeline assets launch, operating leverage compounds.
7. **Valuation reset already priced in (~9x P/E)** — MRK trades at a meaningful discount to peers (J&J ~17x, LLY ~50x). The Keytruda cliff is largely priced in; positive surprises (faster QLEX conversion, larger WINREVAIR peak, pipeline readouts) re-rate.

#### Bear Case Risks

1. **2028 Keytruda patent cliff — ~$25B+ revenue at risk** — Largest single-product patent cliff in pharma history. US composition-of-matter expires 2028; EU 2030. Multiple biosimilars filed (Korea, India, China); FDA biosimilar approvals expected 2028–29.
2. **Pipeline depth gap vs. peers** — Despite >$50B in M&A, Merck's late-stage non-Keytruda pipeline is thinner than peers (LLY, NVO, AZN). Replacement revenue trajectory remains uncertain.
3. **2026 guidance disappointment** — Initial 2026 revenue guide ($65.5–67B) below consensus ($67.6B); EPS guide includes ~$3.65 in Cidara charges. Suggests management's confidence in near-term growth is constrained.
4. **Gardasil China + global HPV exposure** — Multi-quarter Gardasil shipment freeze in China + slowing global HPV demand (already-vaccinated cohorts; demographic headwinds). Gardasil was a ~$9B run-rate franchise now at $8.2B and declining.
5. **IRA Medicare price negotiations** — Keytruda eligible for negotiation in 2028 (small-molecule status to be litigated re biologics). Multiple smaller drugs already subject to negotiation. Pricing pressure structural.
6. **Pipeline single-asset readout risk** — MK-7240 (TL1A IBD from Prometheus), oral PCSK9, vibostolimab (TIGIT), and Terns CML asset all have material binary readouts through 2026–28. Failures dent the post-Keytruda growth narrative.
7. **M&A integration risk** — Multiple large acquisitions in flight (Verona, Terns, Cidara) layered onto Prometheus and Acceleron — operational complexity is non-trivial.

#### Upcoming Events
- **Q2 2026 earnings (late July 2026)**: Keytruda QLEX conversion rates + WINREVAIR + 2026 guide check.
- **Keytruda QLEX adoption metrics**: Quarterly disclosures from Q2 2026 onward.
- **WINREVAIR label expansions**: Multiple Phase 3 readouts in expanded PAH indications.
- **Pipeline readouts**: MK-7240 (TL1A IBD), vibostolimab (TIGIT), oral PCSK9, MK-1084.
- **2027 / 2028 Keytruda biosimilar filings**: First competitive applications expected H2 2027.
- **Cidara acquisition close + integration**: Expected Q1–Q2 2026.
- **Potential Animal Health spin-off**: Possible strategic action through 2026–27.

#### Analyst Sentiment
Consensus rating is **Buy / Overweight** (~60% Buy, 35% Hold, 5% Sell). Price targets cluster $105–115 vs. trading ~$82–88 (~20–30% implied upside). Bull case targets ~$130 on Keytruda QLEX success + WINREVAIR blockbuster; bear case ~$70 on Keytruda cliff materializing without pipeline backstop. Bernstein, Morgan Stanley, BMO maintain Buy; UBS at Neutral; Goldman at Buy with target $115.

#### Research Date
Generated: 2026-05-11

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/mrk
- Full research API: GET /api/v1/research/MRK/memo
- Coverage universe: /stocks